373 related articles for article (PubMed ID: 34185336)
21. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
J Hematol Oncol; 2021 May; 14(1):81. PubMed ID: 34001183
[TBL] [Abstract][Full Text] [Related]
22. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
[TBL] [Abstract][Full Text] [Related]
23. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
Parry H; McIlroy G; Bruton R; Ali M; Stephens C; Damery S; Otter A; McSkeane T; Rolfe H; Faustini S; Wall N; Hillmen P; Pratt G; Paneesha S; Zuo J; Richter A; Moss P
Blood Cancer J; 2021 Jul; 11(7):136. PubMed ID: 34330895
[TBL] [Abstract][Full Text] [Related]
24. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.
Lim SH; Campbell N; Johnson M; Joseph-Pietras D; Collins GP; O'Callaghan A; Fox CP; Ahearne M; Johnson PWM; Goldblatt D; Davies AJ
Lancet Haematol; 2021 Aug; 8(8):e542-e544. PubMed ID: 34224667
[No Abstract] [Full Text] [Related]
25. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
26. Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
Togashi K; Hatakeyama S; Yoneyama T; Hamaya T; Narita T; Fujita N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
Int J Urol; 2022 Jul; 29(7):733-739. PubMed ID: 35362143
[TBL] [Abstract][Full Text] [Related]
27. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Pérez Potti A; Rivera Ballesteros O; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Loré K; Sobkowiak MJ; Gabarrini G; Healy K; Sällberg Chen M; Alici E; Björkström NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren HG
Mol Med; 2022 Feb; 28(1):20. PubMed ID: 35135470
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study.
Salmerón Ríos S; Cortés Zamora EB; Avendaño Céspedes A; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Mas Romero M; Tabernero Sahuquillo MT; Blas Señalada JJ; Murillo Romero A; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Lauschke VM; Stebbing J; Abizanda P
J Am Geriatr Soc; 2022 Mar; 70(3):650-658. PubMed ID: 34894403
[TBL] [Abstract][Full Text] [Related]
29. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
30. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L
JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863
[TBL] [Abstract][Full Text] [Related]
31. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.
Re D; Seitz-Polski B; Brglez V; Carles M; Graça D; Benzaken S; Liguori S; Zahreddine K; Delforge M; Bailly-Maitre B; Verrière B; Chamorey E; Barrière J
Nat Commun; 2022 Feb; 13(1):864. PubMed ID: 35165284
[TBL] [Abstract][Full Text] [Related]
32. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
Gavriatopoulou M; Terpos E; Kastritis E; Briasoulis A; Gumeni S; Ntanasis-Stathopoulos I; Sklirou AD; Malandrakis P; Eleutherakis-Papaiakovou E; Migkou M; Trougakos IP; Dimopoulos MA
Clin Exp Med; 2022 May; 22(2):319-323. PubMed ID: 34283338
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
34. Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
Fukushima J Med Sci; 2022 Apr; 68(1):67-70. PubMed ID: 35228456
[TBL] [Abstract][Full Text] [Related]
35. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.
Marasco V; Carniti C; Guidetti A; Farina L; Magni M; Miceli R; Calabretta L; Verderio P; Ljevar S; Serpenti F; Morelli D; Apolone G; Ippolito G; Agrati C; Corradini P
Br J Haematol; 2022 Feb; 196(3):548-558. PubMed ID: 34649298
[TBL] [Abstract][Full Text] [Related]
36. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
37. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.
Ligumsky H; Safadi E; Etan T; Vaknin N; Waller M; Croll A; Nikolaevski-Berlin A; Greenberg I; Halperin T; Wasserman A; Galazan L; Arber N; Wolf I
J Natl Cancer Inst; 2022 Feb; 114(2):203-209. PubMed ID: 34453830
[TBL] [Abstract][Full Text] [Related]
39. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
40. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Schmitt AM; Tippu Z; Farag S; Rogiers A; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Barber T; Emslie-Henry A; Caulfield-Lynch N; Byrne F; Shum B; Gerard CL; Deng D; Kjaer S; Song OR; Queval C; Kavanagh C; Wall EC; Carr EJ; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Shea RL; Gardner G; Murray D; Yousaf N; Jhanji S; Van As N; Young K; Furness AJS; Pickering L; Beale R; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Howell M; Nicholson E; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Cancer Cell; 2022 Feb; 40(2):114-116. PubMed ID: 34968417
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
